Molecule of the Month: MDM2 and Cancer
MDM2 controls the action of p53 tumor suppressor, making it a target for cancer chemotherapy.
Guarding the Guardian
Exploring the Structure
The interaction between MDM2 and p53 is an attractive target for cancer chemotherapy, because drugs that break this interaction would activate p53, killing the cancer cell. Several effective inhibitors have been discovered that bind at the site on MDM2 that recognizes p53. These include the small molecule Nutlin (PDB entry 1rv1) and SAH-p53-8, a small peptide taken from p53 and stapled in the proper conformation by a linker (PDB entry 3v3b, linker shown in green). To explore the complexes of these inhibitors with MDM2, click on the picture for an interactive JSmol.
Topics for Further Discussion
- Structures of several domains of MDMX are also available in the PDB archive. Try searching for “MDMX”.
- You can explore the interaction of inhibitors with MDM2 using the Ligand View page. For example, look at the interaction in PDB entry 1rv1.
June 2019, David Goodsellhttp://doi.org/10.2210/rcsb_pdb/mom_2019_6